- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03477968
ThRombosis ExclUsion STudy (TRUST)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study population will be selected from prospective, consecutive ambulatory outpatients suspected of having venous thromboembolism. Patients will be diagnosed for VTE (PE or DVT) based on local standard of care. Samples will be collected (additional blood draw or additional volume during blood draw) for future testing with new D-Dimer assay.
In case of Low/Moderate PTP score and negative VTE diagnosis, patients will be followed for 3 months to evaluate potential development of deep venous thrombosis and/or pulmonary embolism.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- Cliniques Universitaires St Luc
-
-
-
-
-
Angers, France
- CHU
-
Dijon, France
- CHU
-
Grenoble, France
- CHU
-
Rouen, France
- CHU
-
-
-
-
-
Bologna, Italy
- University Hospital S. Orsola-Mapighi
-
-
-
-
-
Sevilla, Spain
- Hospital Universitario Virgen del Rocio
-
Soria, Spain
- General Hospital
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health
-
-
Kentucky
-
Campbellsville, Kentucky, United States, 42718
- Taylor regional Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Hemostasis and Thrombosis Research Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Hospital
-
Bethlehem, Pennsylvania, United States, 18015
- St Luke's University Health Network
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson University Hospital
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is > 80 years old.
Patient presents at least one of these symptoms indicative of proximal DVT or PE:
- symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,
- symptoms for PE: hemoptysis, lung related chest pain, dyspnea.
- Patient provides written informed consent to participate in the study
- Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone
Exclusion Criteria:
Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:
- Fibrinolytic therapy within the previous seven (7) days,
- Disseminated intravascular coagulation
- Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,
- Deep hematoma diagnosed by imaging techniques within the previous one (1) month,
- Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),
- Sepsis, severe infections, pneumonia within the previous 1 month,
- Known liver cirrhosis,
- Pregnancy or having delivered within the previous 1 month,
- Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),
- Sickle cell disease,
- Patients presenting with a suspect thrombotic event related to catheter implantation
- Ongoing therapeutic anticoagulants (curative and preventive regimen) started twenty four (24) hours or more before blood draw (except aspirin and platelet inhibitors)
- Previous anticoagulant therapy stopped less than three (3) months before blood draw (except aspirin and platelet inhibitors)
- Patients with previous DVT/PE occurred less than three (3) months from screening.
- Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)
- Patients with known tissue plasminogen activator (tPA) deficiency
- Patient participating or who has participated within one month of enrolment in another investigational study
- Major co-morbid condition(s) or other reasons that could limit the patients ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PE
Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment completed for this group : 13th February 2020 |
Measuring the level of DDimer in blood sample
|
DVT
Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development. Enrolment on going |
Measuring the level of DDimer in blood sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VTE Exclusion
Time Frame: Up to 4 months for patients with 3 months follow-up
|
To demonstrate the ability of new D-Dimer assay combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism or deep venous thrombosis as measured by Negative Predictive Value and sensitivity
|
Up to 4 months for patients with 3 months follow-up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRUST study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on DDimer test
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
Guven Health GroupCompletedAthletic Performance | Physical Fitness | Handball Players | Cross-sectional StudiesTurkey
-
French National Agency for Research on AIDS and...Completed
-
University of FloridaCompletedParkinson Disease (PD)United States
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
University of MichiganCompletedAntidepressants Causing Adverse Effects in Therapeutic UseUnited States